Brendan Halloran1, Jessica Chang, David Q Shih, Dermot McGovern, Konrad Famulski, Chad Evaschesen, Richard N Fedorak, Aducio Thiesen, Stephan Targan, Philip F Halloran. 1. *Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada; †F. Widjaja Foundation, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California; ‡Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada; §Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; and ‖Division of Nephrology and Transplant Immunology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Abstract
BACKGROUND: As a T cell-mediated disease of the colonic epithelium, ulcerative colitis (UC) is likely to share pathogenic elements with other T cell-mediated inflammatory diseases. Recently, microarray analysis revealed large-scale molecular changes in T cell-mediated rejection of kidney and heart transplants. We hypothesized that similar disturbances might be operating in UC and could provide insights into responsiveness to therapy. METHODS: We studied 56 colon biopsies from patients with colitis characterizing the clinical and histological features and using microarrays to define the messenger RNA phenotype. We expressed the microarray results using previously defined pathogenesis-based transcript sets. We also studied 48 published microarray files from human colon biopsies downloaded from the Gene Expression Omnibus database, classified by response to infliximab therapy, to examine whether the molecular measurements derived from our studies correlated with nonresponsiveness to treatment. RESULTS: UC biopsies manifested coordinate transcript changes resembling rejecting transplants, with effector T cell, IFNG-induced, macrophage, and injury transcripts increasing while parenchymal transcripts decreased. The disturbance in gene expression, summarized as principal component 1 (PC1), correlated with conventional clinical and histologic assessments. When assessed in microarray results from published studies, the disturbance (PC1) predicted response to infliximab: patients with intense disturbance did not achieve clinical response, although quantitative improvement was seen even in many clinical nonresponders. Similar changes were seen in Crohn's colitis. CONCLUSIONS: The molecular phenotype of UC manifests a large-scale coordinate disturbance reflecting changes in inflammatory cells and parenchymal elements that correlates with conventional features and predicts response to infliximab.
BACKGROUND: As a T cell-mediated disease of the colonic epithelium, ulcerative colitis (UC) is likely to share pathogenic elements with other T cell-mediated inflammatory diseases. Recently, microarray analysis revealed large-scale molecular changes in T cell-mediated rejection of kidney and heart transplants. We hypothesized that similar disturbances might be operating in UC and could provide insights into responsiveness to therapy. METHODS: We studied 56 colon biopsies from patients with colitis characterizing the clinical and histological features and using microarrays to define the messenger RNA phenotype. We expressed the microarray results using previously defined pathogenesis-based transcript sets. We also studied 48 published microarray files from human colon biopsies downloaded from the Gene Expression Omnibus database, classified by response to infliximab therapy, to examine whether the molecular measurements derived from our studies correlated with nonresponsiveness to treatment. RESULTS: UC biopsies manifested coordinate transcript changes resembling rejecting transplants, with effector T cell, IFNG-induced, macrophage, and injury transcripts increasing while parenchymal transcripts decreased. The disturbance in gene expression, summarized as principal component 1 (PC1), correlated with conventional clinical and histologic assessments. When assessed in microarray results from published studies, the disturbance (PC1) predicted response to infliximab: patients with intense disturbance did not achieve clinical response, although quantitative improvement was seen even in many clinical nonresponders. Similar changes were seen in Crohn's colitis. CONCLUSIONS: The molecular phenotype of UC manifests a large-scale coordinate disturbance reflecting changes in inflammatory cells and parenchymal elements that correlates with conventional features and predicts response to infliximab.
Authors: Linda A Feagins; Shelby D Melton; Ramiz Iqbal; Kerry B Dunbar; Stuart J Spechler Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: J Reeve; J Sellarés; M Mengel; B Sis; A Skene; L Hidalgo; D G de Freitas; K S Famulski; P F Halloran Journal: Am J Transplant Date: 2013-01-28 Impact factor: 8.086
Authors: Konrad S Famulski; Declan G de Freitas; Chatchai Kreepala; Jessica Chang; Joana Sellares; Banu Sis; Gunilla Einecke; Michael Mengel; Jeff Reeve; Philip F Halloran Journal: J Am Soc Nephrol Date: 2012-02-16 Impact factor: 10.121
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Ingrid Arijs; Roel Quintens; Leentje Van Lommel; Kristel Van Steen; Gert De Hertogh; Katleen Lemaire; Anica Schraenen; Clémentine Perrier; Gert Van Assche; Séverine Vermeire; Karel Geboes; Frans Schuit; Paul Rutgeerts Journal: Inflamm Bowel Dis Date: 2010-12 Impact factor: 5.325
Authors: Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325
Authors: Shuji Mitsuhashi; Linda Feldbrügge; Eva Csizmadia; Masato Mitsuhashi; Simon C Robson; Alan C Moss Journal: Inflamm Bowel Dis Date: 2016-07 Impact factor: 5.325
Authors: Soon Man Yoon; Talin Haritunians; Sultan Chhina; Zhenqiu Liu; Shaohong Yang; Carol Landers; Dalin Li; Byong Duk Ye; David Shih; Eric A Vasiliauskas; Andrew Ippoliti; Shervin Rabizadeh; Stephan R Targan; Gil Y Melmed; Dermot P B McGovern Journal: Inflamm Bowel Dis Date: 2017-08 Impact factor: 5.325
Authors: Douglas K Brubaker; Manu P Kumar; Evan L Chiswick; Cecil Gregg; Alina Starchenko; Paige N Vega; Austin N Southard-Smith; Alan J Simmons; Elizabeth A Scoville; Lori A Coburn; Keith T Wilson; Ken S Lau; Douglas A Lauffenburger Journal: Sci Signal Date: 2020-08-04 Impact factor: 8.192